Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response

ABSTRACT: SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response

PROVIDER: PRJNA888044 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response

Project description:After exposing a panel of non-small cell lung cancer (NSCLC) cell lines to cytotoxic CD8+ T-cells, we found SERPINB9 to be the most differentially expressed gene between the cell lines most and least resistant to T-cell killing.

2022-10-12 | GSE214992 | GEO

<i>SERPINB9</i> is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.

Project description:Immunotherapies, in particular immune checkpoint blockade (ICB), have improved the clinical outcome of cancer patients, although many fail to mount a durable response. Several resistance mechanisms have been identified, but our understanding of the requirements for a robust ICB response is incomplete. We have engineered an MHC I/antigen: TCR-matched panel of human NSCLC cancer and T cells to identify tumor cell-intrinsic T cell resistance mechanisms. The top differentially expressed gene in resistant tumor cells was SERPINB9. This serine protease inhibitor of the effector T cell-derived molecule granzyme B prevents caspase-mediated tumor apoptosis. Concordantly, we show that genetic ablation of SERPINB9 reverts T cell resistance of NSCLC cell lines, whereas its overexpression reduces T cell sensitivity. SERPINB9 expression in NSCLC strongly correlates with a mesenchymal phenotype. We also find that SERPINB9 is commonly amplified in cancer, particularly melanoma in which it is indicative of poor prognosis. Single-cell RNA sequencing of ICB-treated melanomas revealed that SERPINB9 expression is elevated not only in cells from post- versus pre-treatment cancers, but also in ICB-refractory cancers. In NSCLC we commonly observed rare SERPINB9-positive cancer cells, possibly accounting for reservoirs of ICB-resistant cells. While underscoring SERPINB9 as a potential target to combat immunotherapy resistance, these results suggest its potential to serve as a prognostic and predictive biomarker.

| S-EPMC9710519 | biostudies-literature

Circulating PMN-MDSCs correlates with poor prognosis in metastatic hormone sensitive prostate cancer

Project description:Circulating PMN-MDSCs correlates with poor prognosis in metastatic hormone sensitive prostate cancer

| PRJNA853305 | ENA

IMMUNE CORRELATES OF RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN ACUTE MYELOID LEUKAEMIA

Project description:IMMUNE CORRELATES OF RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN ACUTE MYELOID LEUKAEMIA

| PRJNA741507 | ENA

Genomic Correlates of Response and Resistance to Immune Checkpoint Blockade in Solid Tumors

Project description:Genomic Correlates of Response and Resistance to Immune Checkpoint Blockade in Solid Tumors

| PRJNA445758 | ENA

Genomic Correlates of Response and Resistance to Immune Checkpoint Blockade in Solid Tumors

Project description:Genomic Correlates of Response and Resistance to Immune Checkpoint Blockade in Solid Tumors

| PRJNA445759 | ENA

19p loss is significantly enriched in older age neuroblastoma patients and correlates with poor prognosis

Project description:19p loss is significantly enriched in older age neuroblastoma patients and correlates with poor prognosis

| PRJNA606780 | ENA

RNA-seq of HUVECs in two models of CFTR blockade

Project description:To unravel CFTR function in endothelial cells (HUVECs), we used two complementary approaches to induce CFTR blockade: (i) the allosteric CFTR inhibitor CFTRinh-(172) which is commonly used in CF research, and (ii) CFTR-specific short hairpin RNAs (shRNA).

2020-10-31 | E-MTAB-8599 | biostudies-arrayexpress

19p loss is significantly enriched in older age neuroblastoma patients and correlates with poor prognosis (Agilent-022060)

Project description:19p loss is significantly enriched in older age neuroblastoma patients and correlates with poor prognosis (Agilent-022060)

| PRJNA606782 | ENA

19p loss is significantly enriched in older age neuroblastoma patients and correlates with poor prognosis (Agilent-014950)

Project description:19p loss is significantly enriched in older age neuroblastoma patients and correlates with poor prognosis (Agilent-014950)

| PRJNA606784 | ENA